Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Prashanth

Showing results (61-70 of 66) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 66 results.
Frontiers in Artificial Intelligence|July 5, 2022
Cross Country Determinants of Investors' Sentiments Prediction in Emerging Markets Using ANNAnanth Rao, Manoj Kumar M V, Immanuel Azaad Moonesar, et al.
Vaccine|April 18, 2024
Immunogenicity and safety of a 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14™) administered to 6-8 weeks old healthy Indian Infants: A single blind, randomized, active-controlled, Phase-III studyRamesh V Matur, Subhash Thuluva, Subbareddy Gunneri, et al.
Vaccine|September 2, 2023
Immunogenicity and safety of Mebella™ vaccine developed by Human Biologicals Institute in a Phase II/III, randomized, multicentric, non-inferiority studySai Krishna Susarla, Rahul Jahagirdar, Kheya Ghosh Uttam, et al.
Health Policy and Planning|October 6, 2020
What role can health policy and systems research play in supporting responses to COVID-19 that strengthen socially just health systems?Lucy Gilson, Bruno Marchal, Irene Ayepong, et al.
Vaccine: X|September 27, 2022
Lot-to-lot consistency of a hexavalent DTwP-IPV-HB-PRP∼T vaccine and non-inferiority to separate DTwP-HB-PRP∼T and IPV antigen-matching vaccines at 6-8, 10-12, and 14-16 weeks of age co-administered with oral rotavirus vaccine in healthy infants in India: A multi-center, randomized, controlled studyS Mangarule, S Prashanth, A Kawade, et al.
BMJ Global Health|July 29, 2020
The COVID-19 pandemic: diverse contexts; different epidemics-how and why?Wim Van Damme, Ritwik Dahake, Alexandre Delamou, et al.
Pageof 7

Showing results (61-70 of 66) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 66 results.
Frontiers in Artificial Intelligence|July 5, 2022
Cross Country Determinants of Investors' Sentiments Prediction in Emerging Markets Using ANNAnanth Rao, Manoj Kumar M V, Immanuel Azaad Moonesar, et al.
Vaccine|April 18, 2024
Immunogenicity and safety of a 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14™) administered to 6-8 weeks old healthy Indian Infants: A single blind, randomized, active-controlled, Phase-III studyRamesh V Matur, Subhash Thuluva, Subbareddy Gunneri, et al.
Vaccine|September 2, 2023
Immunogenicity and safety of Mebella™ vaccine developed by Human Biologicals Institute in a Phase II/III, randomized, multicentric, non-inferiority studySai Krishna Susarla, Rahul Jahagirdar, Kheya Ghosh Uttam, et al.
Health Policy and Planning|October 6, 2020
What role can health policy and systems research play in supporting responses to COVID-19 that strengthen socially just health systems?Lucy Gilson, Bruno Marchal, Irene Ayepong, et al.
Vaccine: X|September 27, 2022
Lot-to-lot consistency of a hexavalent DTwP-IPV-HB-PRP∼T vaccine and non-inferiority to separate DTwP-HB-PRP∼T and IPV antigen-matching vaccines at 6-8, 10-12, and 14-16 weeks of age co-administered with oral rotavirus vaccine in healthy infants in India: A multi-center, randomized, controlled studyS Mangarule, S Prashanth, A Kawade, et al.
BMJ Global Health|July 29, 2020
The COVID-19 pandemic: diverse contexts; different epidemics-how and why?Wim Van Damme, Ritwik Dahake, Alexandre Delamou, et al.
Pageof 7